In last trading session, RAPT Therapeutics Inc (NASDAQ:RAPT) saw 0.38 million shares changing hands with its beta currently measuring -0.27. Company’s recent per share price level of $1.14 trading at -$0.03 or -2.56% at ring of the bell on the day assigns it a market valuation of $150.49M. That closing price of RAPT’s stock is at a discount of -746.49% from its 52-week high price of $9.65 and is indicating a premium of 30.7% from its 52-week low price of $0.79. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.5 million shares which gives us an average trading volume of 3.48 million if we extend that period to 3-months.
For RAPT Therapeutics Inc (RAPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.14 in the current quarter.
RAPT Therapeutics Inc (NASDAQ:RAPT) trade information
Upright in the red during last session for losing -2.56%, in the last five days RAPT remained trading in the green while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $1.14 price level, adding 12.31% to its value on the day. RAPT Therapeutics Inc’s shares saw a change of -27.85% in year-to-date performance and have moved 0.88% in past 5-day. RAPT Therapeutics Inc (NASDAQ:RAPT) showed a performance of -1.72% in past 30-days. Number of shares sold short was 2.63 million shares which calculate 4.67 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2 to the stock, which implies a rise of 43.0% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 2. It follows that stock’s current price would drop -75.44% in reaching the projected high whereas dropping to the targeted low would mean a loss of -75.44% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.10% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 81.30% while estimates for its earnings growth in next 5 years are of 42.80%.
RAPT Therapeutics Inc (NASDAQ:RAPT)’s Major holders
Insiders are in possession of 0.49% of company’s total shares while institution are holding 96.43 percent of that, with stock having share float percentage of 96.90%. Investors also watch the number of corporate investors in a company very closely, which is 96.43% institutions for RAPT Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at RAPT for having 5.24 million shares of worth $15.97 million. And as of 2024-06-30, it was holding 13.5546 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 3.11 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.0472 of outstanding shares, having a total worth of $9.48 million.
On the other hand, Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.49 shares of worth $1.7 million or 1.13% of the total outstanding shares. The later fund manager was in possession of 1.05 shares on Dec 31, 2024 , making its stake of worth around $1.2 million in the company or a holder of 0.79% of company’s stock.
